{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Oswald S"],"funding":["NIGMS NIH HHS"],"pagination":["506-13"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3667671"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["91(3)"],"pubmed_abstract":["Hypercholesterolemia frequently occurs in patients treated with efavirenz who cannot be treated adequately with statins because of drug interactions. These patients may benefit from cholesterol-lowering therapy with ezetimibe. This study determined the influence of single-dose and multiple-dose efavirenz (400 mg/day for 9 days) on the pharmacokinetics and sterol-lowering of ezetimibe (10 mg) in 12 healthy subjects. In addition, the influence of efavirenz on genome-wide intestinal expression and in vitro function of ABCB1, ABCC2, UGT1A1, and OATP1B1 was studied. Efavirenz (multiple dose) had no influence on the pharmacokinetics and lipid-lowering functions of ezetimibe. Intestinal expression of enzymes and transporters (e.g., ABCB1, ABCC2, and UGT1A1) was not affected by chronic efavirenz. "],"journal":["Clinical pharmacology and therapeutics"],"pubmed_title":["Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers."],"pmcid":["PMC3667671"],"funding_grant_id":["R01GM078501","R01 GM078501"],"pubmed_authors":["Keiser M","Marinova M","Lutjohann D","Runge D","Nassif A","Jia J","Ogburn ET","Desta Z","Mostertz J","Siegmund W","Meyer zu Schwabedissen HE","Hubeny A","Ulrich A","Oswald S","Modess C","Kroemer HK"],"additional_accession":[]},"is_claimable":false,"name":"Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.","description":"Hypercholesterolemia frequently occurs in patients treated with efavirenz who cannot be treated adequately with statins because of drug interactions. These patients may benefit from cholesterol-lowering therapy with ezetimibe. This study determined the influence of single-dose and multiple-dose efavirenz (400 mg/day for 9 days) on the pharmacokinetics and sterol-lowering of ezetimibe (10 mg) in 12 healthy subjects. In addition, the influence of efavirenz on genome-wide intestinal expression and in vitro function of ABCB1, ABCC2, UGT1A1, and OATP1B1 was studied. Efavirenz (multiple dose) had no influence on the pharmacokinetics and lipid-lowering functions of ezetimibe. Intestinal expression of enzymes and transporters (e.g., ABCB1, ABCC2, and UGT1A1) was not affected by chronic efavirenz. ","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Mar","modification":"2025-06-01T12:29:54.365Z","creation":"2025-06-01T12:29:54.365Z"},"accession":"S-EPMC3667671","cross_references":{"pubmed":["22297387"],"doi":["10.1038/clpt.2011.255"]}}